Case report: Recurrence of anti-myeloperoxidase pauci-immune crescentic glomerulonephritis in a kidney transplant recipient; potential association with HLA antigens and seropositivity? - Report - MDSpire

Case report: Recurrence of anti-myeloperoxidase pauci-immune crescentic glomerulonephritis in a kidney transplant recipient; potential association with HLA antigens and seropositivity?

  • By

  • Woojin James Chon

  • Choli Hartono

  • Elena-Rodica Vasilescu

  • David Serur

  • Ibrahim Batal

  • June 17, 2026

  • 0 min

Share

Clinical Report: Early Recurrence of Anti-Myeloperoxidase AAV in Kidney Transplant

Overview

This report details a case of early recurrence of anti-MPO AAV in a kidney transplant patient who shared permissive HLA antigens with the donor and had detectable anti-MPO antibodies post-transplant. The findings underscore the importance of monitoring for disease recurrence in at-risk patients, particularly those with shared HLA antigens.

Background

Anti-MPO AAV is a serious condition that can lead to rapid kidney failure and is characterized by pauci-immune crescentic glomerulonephritis. Recurrence of this condition post-kidney transplantation is rare but can significantly impact graft survival and patient outcomes. Understanding the immunological factors, including HLA antigen compatibility and the role of anti-MPO antibodies, is crucial for managing these patients effectively.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

Early recurrence of anti-MPO AAV was observed in a kidney transplant recipient. The patient shared HLA-DR4 and HLA-DQ7 antigens with the deceased donor. Post-transplant, the patient had elevated anti-MPO antibodies, which may be linked to recurrence. Thirteen additional cases of anti-MPO AAV in native kidneys did not show recurrence post-transplant. Close monitoring for disease recurrence is recommended in patients with known risk factors.

Clinical Implications

Clinicians should be vigilant in monitoring kidney transplant recipients with a history of anti-MPO AAV, especially those with shared HLA antigens and detectable anti-MPO antibodies. Early detection and intervention may improve outcomes in these high-risk patients through tailored monitoring strategies.

Conclusion

This case highlights the potential for early recurrence of anti-MPO AAV in kidney transplant patients and emphasizes the need for careful immunological assessment and monitoring post-transplant.

Related Resources & Content

  1. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
  2. Outcomes of Renal Transplantation in ANCA-Associated Vasculitis: A Systematic Review and Meta-Analysis - PMC
  3. Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression - PMC
  4. Frontiers in Immunology — Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report
  5. Frontiers in Immunology — Recurrence of IgA nephropathy in a kidney transplant patient successfully treated with iptacopan—a case report
  6. Frontiers in Immunology — Association of PIRCHE scores and allograft injury in kidney transplant recipients
  7. Frontiers in Immunology — Case Report: Anti-glomerular basement membrane disease during pregnancy with favorable renal outcome, sequential biopsies, and dual anti-α1/α3(IV) and anti-LM521 antibodies
  8. Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report
  9. Recurrence of IgA nephropathy in a kidney transplant patient successfully treated with iptacopan—a case report
  10. Association of PIRCHE scores and allograft injury in kidney transplant recipients
  11. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
  12. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | New England Journal of Medicine
  13. KDOQI Provides U.S. Clinical Perspective on KDIGO 2024 Guideline for ANCA-Associated Vasculitis | National Kidney Foundation
  14. Outcomes of Renal Transplantation in ANCA-Associated Vasculitis: A Systematic Review and Meta-Analysis - PMC
  15. Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression - PMC
  16. Avacopan for the Treatment of ANCA-Associated Vasculitis | New England Journal of Medicine
  17. Successful use of eculizumab in immediate ANCA vasculitis recurrence in a pediatric kidney transplant - Peterson - 2024 - Pediatric Transplantation - Wiley Online Library
  18. Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management | Nature Reviews Rheumatology
  19. Frontiers | Association of HLA-class II alleles with risk of relapse in myeloperoxidase-antineutrophil cytoplasmic antibody positive vasculitis in the Japanese population
  20. Frontiers | Recurrence of anti-Myeloperoxidase Pauci-immune Crescentic Glomerulonephritis in a Kidney Transplant Recipient; Potential Association with HLA antigens and seropositivity?

Original Source(s)

Related Content